Alpha 2.0
Login Register
» Authors » Charles A Knirsch

Charles A Knirsch

Explore the profile of Charles A Knirsch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 79
Followers 0
Related Specialties
Infectious Diseases
Tropical Medicine
General Medicine
Top 10 Co-Authors
Paul Glue
Demissie Alemayehu
Guy W Amsden
Emma N Andrews
Jack Cook
Bharat Damle
Jacob A Kumaresan
Hartmut Lode
Milton L Pressler
Pascal J de Caprariis
Published In
PLoS Negl Trop Dis
Lancet Infect Dis
Clin Transl Sci
Treat Respir Med
Clin Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin
Cook J, Pressler M, Damle B, Alemayehu D, Knirsch C
Clin Transl Sci . 2020 Sep; 14(1):106-112. PMID: 32956575
Increased use of azithromycin (AZ) in treating infections associated with coronavirus disease 2019 (COVID-19) and reports of increased incidence of prolonged corrected QT (QTc) interval associated with AZ used with...
2.
Azithromycin and the risk of cardiovascular death
Knirsch C, Chandra R
N Engl J Med . 2012 Aug; 367(8):772-3. PMID: 22913693
No abstract available.
3.
A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens
Alemayehu D, Quinn J, Cook J, Kunkel M, Knirsch C
Clin Infect Dis . 2012 May; 55(4):562-7. PMID: 22610933
Multidrug-resistant (MDR) gram-negative pathogens pose a major threat to patients worldwide. Although the organisms remain relatively uncommon overall, their incidence is steadily increasing with associated increases in mortality and pharmacoeconomic...
4.
Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting
Alemayehu D, Andrews E, Glue P, Knirsch C
PLoS Negl Trop Dis . 2010 Feb; 4(1):e564. PMID: 20126267
No abstract available.
5.
The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis
El-Tahtawy A, Glue P, Andrews E, Mardekian J, Amsden G, Knirsch C
PLoS Negl Trop Dis . 2008 May; 2(5):e236. PMID: 18478051
Background: A recent drug interaction study reported that when azithromycin was administered with the combination of ivermectin and albendazole, there were modest increases in ivermectin pharmacokinetic parameters. Data from this...
6.
Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers
Amsden G, Gregory T, Michalak C, Glue P, Knirsch C
Am J Trop Med Hyg . 2007 Jun; 76(6):1153-7. PMID: 17556628
Azithromycin is a critical component of an integrated disease elimination program against trachoma. This study was conducted to evaluate whether azithromycin has a pharmacokinetic interaction with the combination of ivermectin...
7.
Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia
Zervos M, Mandell L, Vrooman P, Andrews C, McIvor A, Abdulla R, et al.
Treat Respir Med . 2004 Dec; 3(5):329-36. PMID: 15606222
Objective: To compare the efficacy and tolerability of ceftriaxone plus azithromycin with those of levofloxacin in the treatment of hospitalized patients with moderate to severe community-acquired pneumonia (CAP). Design: Randomized,...
8.
The possibility of eliminating blinding trachoma
Mecaskey J, Knirsch C, Kumaresan J, Cook J
Lancet Infect Dis . 2003 Nov; 3(11):728-34. PMID: 14592604
Global elimination of blinding trachoma, the world's leading preventable cause of blindness, now seems possible. The disease, which persists most severely in the poorest parts of Africa and Asia, is...